Abstract
Prognostic Factors for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
Highlights
Ovarian cancer is one of the most lethal gynaecological cancers
Chemotherapy following surgery is required with the exception of stage IA in the hope to achieve complete clinical remission after surgical procedure
The results of the study The Descriptive Evaluation of preoperative Selection KriTeria for OPerability in recurrent OVARian cancer (DESKTOP OVAR) I conducted by Harter P, et al concluded that patients who underwent secondary cytoreduction for epithelial ovarian cancer sensitive to chemotherapy showed that only complete resection was associated with prolonged survival
Summary
Ovarian cancer is one of the most lethal gynaecological cancers. Complete surgical procedure, mentioned in NCCN Guidelines Version 3.2014, is essential for correct staging and management of these patients [1]. Chemotherapy following surgery is required with the exception of stage IA in the hope to achieve complete clinical remission after surgical procedure. In advanced ovarian cancer complete clinical response to systemic chemotherapy is achieved only in about 50% and most of them, around 60% of the patients with advanced epithelial ovarian cancer, will develop recurrent disease or drug resistance [2]. Even if at the time of second look surgery no lesion is identified 30%-50% of patients will develop recurrence [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
